Veterinary Practice Valuation UK 2026

The UK veterinary sector has just emerged from the most extensive regulatory review of veterinary services in a generation. On 24 March 2026 the Competition and Markets Authority published its Final Report, confirming 14 binding remedies covering price transparency, prescription fee caps, ownership disclosure and complaints handling. Critically for owners weighing a sale, the CMA stopped well short of forced divestitures or wholesale price controls. The six largest groups, holding approximately 60% of the UK's £6.7bn pet care market, can keep growing. IVC Evidensia is now openly preparing a multi-billion pound IPO and CVS Group is restarting UK acquisitions after pausing through the investigation.

For independent UK vet practice owners, the regulatory cloud has lifted. The 12 to 24 months ahead represent the strongest seller's market since the 2021-2022 corporate consolidation peak. For commentary on buyer activity, multiples and deal structures across the UK veterinary M&A landscape, see our veterinary M&A advisory page.

This guide breaks down current UK veterinary valuation methodologies, the post-CMA regulatory backdrop, named buyer groups, the EBITDA multiple ranges seen in 2026 deals, the 11 value drivers buyers price, and a sale-readiness checklist for owners 12 to 36 months from exit.

The post-CMA regulatory landscape

The CMA market investigation ran from 2023 to March 2026 and produced regulatory clarity that materially affects practice valuations.

What was confirmed. Per Bird & Bird's review of the Final Report, the CMA confirmed 14 remedies grouped into six categories: ownership and price transparency, treatment information, prescribing, out-of-hours contracts, cremation services and complaints management. Practices must publish defined price lists, provide written estimates for treatments expected to cost £500 or more, cap written prescription fees at £21 (£12.50 for additional medicines), and have written policies ensuring vets can provide independent and impartial advice.

What was avoided. No forced divestitures of existing groups. No general price controls. No mandatory split between veterinary practices and adjacent services such as labs, pharmacies or crematoria. The Final Report does not impose structural separation - it imposes transparency, complaints standards and prescription fee discipline.

Timeline. Per GOV.UK's CMA timetable, the statutory deadline for putting Orders in place is 23 September 2026. Most remedies enter force three to twelve months after the Order, with large veterinary groups (LVGs) implementing transparency remedies by December 2026 and smaller providers (under 15 practices) generally given an additional three months. This matters for sale timing: buyers will increasingly require diligence comfort that target practices are remedy-ready.

Compliance cost. The CMA estimates an RCVS levy of £150 to £250 initially per practice and £450 to £550 annually thereafter. Sophisticated buyers are pricing this into EBITDA adjustments.

The practical implication is that the regulatory overhang that suppressed UK veterinary M&A activity for two years has been replaced by a finite, well-defined compliance package. Buyer confidence is returning. CVS Group's October 2025 results confirmed it is well positioned for further UK acquisitions post-investigation, and IVC Evidensia is reportedly months away from listing.

How UK veterinary practices are valued in 2026

UK veterinary practices in 2026 are valued using two principal methods, with sophisticated buyers using both and triangulating.

EBITDA multiple (the dominant method). Used for practices with £150k+ of normalised earnings. UK veterinary EBITDA multiples in 2026 typically range from 4.5x to 12x depending on scale, growth, vet retention, location and buyer type. Critical inputs: how EBITDA is normalised (owner add-backs, market-rate vet salary substitution for owner clinical time, vehicle and equipment costs, working capital), recurring revenue from pet health plans, and treatment of property where the owner owns the freehold.

Earnings-based revenue benchmarks. Used as a sanity check and for smaller transactions. Single-vet practices in mid-tier locations typically transact at 70% to 110% of turnover; small-animal practices with 3+ vets and pet plan penetration trade at 110% to 180% of turnover; multi-site groups with property held in clean structures trade at 180% to 280% of turnover or above. These ranges reflect the relationship between practice scale, recurring revenue density and the resulting EBITDA multiple uplift.

International reference points sit notably above current UK levels. Ackerman Group's Q1 2026 US veterinary market update reports a weighted average EBITDA multiple of 13.3x in Q1 2026, up from 12.5x in 2025, with A+ hospitals achieving 16x or better. DVM Elite's 2026 valuation guide cites a 6x to 12x EBITDA range for US practices in 2026 depending on scale and buyer type. The UK runs at a discount to the US for now, principally because the CMA overhang has only just lifted - that gap is likely to compress through 2026 and 2027 as corporate buyer appetite normalises.

A real-world UK reference: in October 2025, CVS Group disposed of its UK crematoria operations for initial proceeds of £42.3m, representing a 10x adjusted EBITDA multiple. The transaction confirms that institutional-grade UK veterinary-adjacent assets are pricing at the upper end of the multiple range.

Current EBITDA multiple ranges by practice profile

The table below synthesises ranges from Ackerman Group, DVM Elite, Serenity Vet, Vet Times and DealFlowAgent transaction observations. Assumes clean financials, transferable lease and minimal owner dependency.

Multi-site groups and referral hospitals sit at the top of the range because they are the platform-grade assets that PE-backed groups acquire as bolt-ons into existing portfolios. For owners benchmarking their own practice, our buy-side advisory team maintains UK transaction comparables across each category and can stress-test EBITDA quality, working capital normalisation and net debt definitions before any buyer approach.

The single most important practical observation: the headline EBITDA multiple is one of four levers that determine cash at completion. Working capital adjustments, net debt definition, earn-out structure and property arrangements collectively often move actual cash received by 15% to 25%. Owners focused only on the headline multiple typically leave material value on the table. The same valuation discipline applies across healthcare consolidation more broadly - see our equivalent analysis for dental practice sales in the UK where DSO buyers run almost identical diligence playbooks.

The named UK buyer landscape in 2026

The UK veterinary buyer universe in 2026 sits in five distinct tiers.

Tier 1: The big six corporate consolidators. Together holding around 60% of the UK pet care market.

• IVC Evidensia. UK's largest group with approximately 20% market share. PE-backed (EQT, Silver Lake, Nestle, ADIA among others) and openly preparing a multi-billion pound IPO. Resumed selective UK acquisitions through 2025 and is positioned to be highly acquisitive post-IPO.
• CVS Group. Listed on AIM. UK acquisitions paused during the CMA investigation, now restarting. October 2025 results confirmed continued strategic interest in UK platform expansion, with the disposed crematoria proceeds funding further M&A.
• Pets at Home Vet Group. Vertically integrated through Pets at Home. Around 10% market share. Acquisitive but selective.
• VetPartners. Backed by BC Partners. Active acquirer of premium independent practices.
• Linnaeus (Mars Veterinary Health). Acquired several practices including 8 from the VetPartners/Goddard divestiture in 2022. Continues selective acquisitions.
• Medivet (CVC Capital). Active buy-and-build platform.

Tier 2: Mid-market and specialist groups. Multiple smaller corporate groups acquiring in specific geographies or specialisms (referral, equine, exotic, emergency). Typically offer faster decision-making and slightly more flexibility on deal structure than the big six.

Tier 3: International strategic and PE entrants. US groups such as Mars Veterinary Health (which owns Banfield and VCA in the US in addition to Linnaeus in the UK), and US PE-backed platforms scoping UK platform entry post-CMA clarity.

Tier 4: Independent and search fund buyers. Single-practice and small group buyers, often vet-led with family office or independent sponsor backing. Compete in the £500k to £3m enterprise value range. Typically pay 5x to 7x EBITDA but offer continuity of culture, faster completion and more flexible earn-out structures.

Tier 5: Vet-to-vet sales and management buyouts. A growing segment for owners prioritising clinical continuity over headline value. Multiples typically 4x to 6x but with greater certainty of completion and minimal post-sale lock-in.

The veterinary buyer pyramid mirrors what we see across UK healthcare consolidation - the same PE-backed structures driving dental DSO acquisitions, care home group roll-ups and medispa platform building are deploying capital into veterinary platforms. Owners benchmarking offer quality should treat buyer category, not just headline multiple, as a primary determinant of post-completion experience.

The 11 value drivers that buyers actually price

Sophisticated UK veterinary buyers in 2026 underwrite the same 11 drivers in every transaction. Owners should treat this as a pre-sale checklist.

1. Pet health plan penetration. Percentage of active clients on recurring pet health plans. The single highest-impact recurring revenue driver. Practices above 35% pet plan penetration consistently command premium multiples; below 15% is a red flag for institutional buyers.

2. Client retention and visit frequency. Active client base, retention rate over 24 months, average visit frequency. Buyers diligence the practice management system data directly.

3. Vet retention and team stability. Average vet tenure, employed vet to associate ratio, RCVS standing, locum dependency. Vet turnover above 15% per year materially discounts multiples. Locum-heavy practices are typically uninvestable for the big six.

4. Owner dependency. Percentage of clinical revenue and client relationships dependent on the principal. Practices where the principal is the senior surgeon for high-value cases (orthopaedic, exotics, advanced dental) carry continuity risk. Buyers require evidence of associate or junior vet capability to absorb principal-dependent revenue.

5. Location density and demographic catchment. Dense urban/suburban catchments with good demographics support higher pet plan adoption and premium pricing. Rural locations have a narrower buyer universe and trade at lower multiples.

6. Service mix and revenue per client. Practices with advanced diagnostics (in-house lab, imaging), specialist services (orthopaedic, dental, dermatology, behavioural) and strong dental and prophylactic revenue command higher multiples than basic first-opinion practices.

7. Property quality and lease structure. Freehold premises typically sit outside the EBITDA multiple as a separate property transaction. Leasehold practices require a 10+ year lease (15+ years for corporate buyers) with manageable rent reviews. Per Vet Times, short leases or undocumented owner-to-business leases are the single most common cause of UK veterinary sale delays.

8. Practice management system and digital infrastructure. Cloud-based PMS, online booking, integrated diagnostics and modern client communications. Buyers pay premium multiples for practices they can integrate without ripping out legacy systems.

9. Financial track record and quality of earnings. Three years of accountant-reviewed or audited accounts, separately reported pet plan and clinical revenue, normalised working capital, documented owner add-backs. Quality of Earnings reports are standard at £1m+ EBITDA.

10. CMA remedy readiness. Documented price lists, ownership transparency, complaints process, written estimate procedures and prescription protocols. Practices that are CMA-ready by H2 2026 carry no diligence overhang; those that are not will see buyer indemnity demands and price chips.

11. Growth trajectory. Three-year organic revenue and EBITDA growth, client base expansion, recent investment in equipment or premises supporting future growth. Buyers price trajectory, not just current EBITDA.

The most controllable drivers in a 12 to 24 month pre-sale window are pet plan penetration (a 12-month push from 20% to 35% adoption can move the multiple by 1.0x to 1.5x), CMA remedy readiness, financial track record and lease assignment. Vet retention, owner dependency reduction and service mix expansion take longer to move materially.

Why the 2026 UK supply-demand backdrop favours sellers

Three structural factors are pushing UK veterinary multiples higher through the back half of 2026 and into 2027.

Supply contraction. Ackerman's US data shows that practice transactions globally have declined every year since 2021's peak of over 1,000 practices, falling to around 350 in both 2024 and 2025. UK supply has followed the same pattern, intensified by the CMA overhang. Limited supply against returning corporate appetite creates upward pricing pressure.

Corporate buyer dry powder. IVC Evidensia, CVS, VetPartners, Linnaeus, Medivet and Pets at Home Vet Group all hold acquisition mandates. The pause through 2024 and 2025 has built a backlog of capital looking for the right targets. CVS's October 2025 statement explicitly anticipates "a backlog of independent practice owners wishing to sell" post-CMA - signalling buyer competition will intensify in H2 2026 and 2027. The pattern echoes the broader UK private equity consolidation thesis across building services and healthcare - capital concentration into specialist platforms accelerates wherever regulatory or operational scale benefits exist.

IPO and exit-driven activity. IVC Evidensia's preparation for IPO will likely accelerate its UK acquisition pace to bulk up pre-listing. Other PE-backed platforms reaching the end of their hold periods will look to exit, either to secondary buyers or via IPO, increasing buyer competition for the strongest independent practices.

What can go wrong

UK veterinary sales fail or underperform for predictable reasons.

Property and lease issues. Short or poorly drafted leases, owner-to-business arrangements without formal documentation, and undisclosed dilapidations exposure are the single most common cause of delayed or collapsed UK vet sales. Pre-sale lease and property review is essential.

Vet flight during diligence. Key associate vets leaving between heads of terms and completion is a deal-breaking event. Retention bonuses tied to the SPA, restrictive covenants and clear post-sale clinical roles protect against this.

Earn-out disputes. Cash at completion is typically 60% to 80% of headline price, with the balance contingent on post-completion EBITDA, client retention or pet plan growth targets. Earn-out definition is the most negotiated element of UK vet SPAs in 2026 - clear documentation of how EBITDA is calculated, what synergies are excluded and how disputes are resolved often determines whether sellers receive 100% or 60% of deferred consideration.

CMA remedy non-compliance discovered in diligence. Buyers in H2 2026 onwards will diligence remedy compliance explicitly. Practices that are not remedy-ready will see indemnity demands and price reductions.

Working capital and net debt traps. Aggressive working capital normalisation by buyer accountants and inclusion of items in "net debt" that the seller treated as operating items (deferred income from pet plans, accrued holiday pay, lease liabilities, vehicle finance) can erode cash at completion by 5% to 15%. SPA negotiation on these definitions is critical.

Timing and process

A 24-month pre-sale runway is the standard planning horizon. Owners 5+ years from exit should still focus on the value drivers above - pet plan penetration in particular compounds materially over time. Owners within 24 months should be:

• Engaging a specialist UK veterinary M&A adviser, not a generic small-business broker
• Building a clean 36-month financial track record
• Driving pet plan penetration to 35%+ if currently below
• Reviewing and refreshing the lease (target 15+ years remaining for corporate buyer appeal)
• Reducing owner-dependent clinical revenue through associate development
• Documenting CMA remedy compliance ahead of statutory implementation dates
• Mapping the buyer universe (the right 8 to 15 buyers, not a generic broker mass-mailing)

The 2026 UK market is unusually favourable for veterinary practice sellers. The CMA cloud has lifted, corporate buyer appetite is returning, supply is constrained and IVC Evidensia's likely IPO will pull additional buyer capital into the sector. The risk is not finding a buyer - the risk is choosing the wrong one or selling too early at the wrong price.

DealFlowAgent works with UK veterinary practice owners considering a sale to corporate groups, mid-market consolidators, independent buyers or management. We map the buyer universe, run targeted competitive processes and structure deals that protect both headline price and net cash at completion. If you are within 36 months of an exit, the time to start planning is now. Get in touch with our advisory team for a confidential discussion of your options.

Your Advisory Team

Experienced Dealmakers Lead Your Exit

Every exit is led by a senior advisor who has been through it themselves. Meet the team who will guide you.

Joe Lewin

Founder & Lead Advisor — M&A Specialist

• •4 years in M&A advisory; 22 completed transactions
• •Direct relationships with hundreds of strategic and financial acquirers
• •Raised £2m in funding; placed 3rd of 1,900 at OnStage (the "Y Combinator of Europe")
• •Previously built a mobility and field services business to 30 staff and 6 UK warehouses, then sold via competitive process with an EY M&A partner
• •Full-stack developer of advanced agent systems and second-brain tooling for the M&A process

Joe Thomason

Senior M&A Advisor

• •Previously Analyst at KBS Corporate
• •Analyst at Hampleton Partners, Associate at Tech Credit Partners
• •Worked on 25+ completed transactions (£300k to £120m)
• •Specialist in debt lending for business buyers

Emerson Patton

Sector Specialist: Building, Construction & Trade Services

• •20+ years advising owners in building services, fire safety, HVAC, plumbing, and construction
• •Guided 200+ companies through growth, profit improvement, and exit planning
• •Builds equity value and operational structure long before a sale
• •Partners with DFA to prepare owners for exit while the advisory team runs the sale

Sam Pouyan

Senior M&A Advisor

• •10 years across buy-side and sell-side M&A
• •Former investment banking analyst
• •Expert in financial modelling and deal structuring

James Duboullay

Senior M&A Advisor

• •25+ years across investment banking, M&A and fundraising
• •Sector focus: essential services and software
• •Long-standing relationships with private equity buyers and growth funds
• •Personally advising DealFlowAgent founders for the past four years

Sage

AI Deal Concierge

• •Available 24/7. Monitors every signal in your deal
• •Keeps your advisory team one step ahead at all times
• •Trained on thousands of M&A transactions

Sterling

Buy-Side Deal Origination Agent

• •Engages 12,000+ acquirers to surface live mandates and intent
• •Qualifies buyer fit, budget and timing before introductions
• •Feeds your advisory team with warm, ranked buyer matches

Tim Armoo

Partner & Chief Marketing Officer

• •Founded Fanbytes, scaled revenues to £10m+, exited at multi-eight-figure valuation
• •Advises on multiple M&A deals, invests in early-stage ventures
• •Built 700,000+ follower community teaching founders to scale and sell
• •Partnered with DealFlowAgent to expand access for founders to buyers

Assigned Per Deal

Sector Expert

Industry-Specific M&A Advisor

For every deal, our advisory team includes a sector specialist from that client's specific industry and niche: bringing relationships, insider knowledge, and leverage to support your process and achieve the best acquisition outcome.

INTERVIEWING

Head of M&A

Senior hire — interviewing now

Final-round interviews underway with 100+ applicants. Joining May 2026 to lead the advisory bench across Building Services and Healthcare.

OFFER STAGE

Senior M&A Advisor

New seat — 100+ applicants

Sourced from boutique investment banks and Big-4 corporate finance teams. Joining May–June 2026.

INTERVIEWING

Senior M&A Advisor

Second seat — interviewing

Sector-specialist hire focused on the lower-mid market (£1M–£10M EBITDA). Joining May–June 2026.

We're actively expanding the bench — three senior M&A hires confirmed for May–June 2026. See open roles → Apply now →

Healthcare M&A Specialists

Thinking of selling your healthcare business?

DealFlowAgent is the UK and US's only M&A advisory firm specialising in healthcare businesses. Our trusted advisors leverage industry knowledge, buyer relationships and proprietary technology to help business owners secure multiple acquisition offers at higher valuations.

Talk to a Real Advisor - No Obligation

Speak with Joe or Sam about your situation. No hard sell, no commitment, just honest advice from advisors who've been through it.

What's Your Business Actually Worth?

Our valuation tool gives you a realistic range based on recent comparable transactions in your sector. Takes 3 minutes.

Related Articles